Literature DB >> 11160455

Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.

N D Volkow1, G Wang, J S Fowler, J Logan, M Gerasimov, L Maynard, Y Ding, S J Gatley, A Gifford, D Franceschi.   

Abstract

Methylphenidate (Ritalin) is the most commonly prescribed psychoactive drug in children for the treatment of attention deficit hyperactivity disorder (ADHD), yet the mechanisms responsible for its therapeutic effects are poorly understood. Whereas methylphenidate blocks the dopamine transporter (main mechanism for removal of extracellular dopamine), it is unclear whether at doses used therapeutically it significantly changes extracellular dopamine (DA) concentration. Here we used positron emission tomography and [(11)C]raclopride (D2 receptor radioligand that competes with endogenous DA for binding to the receptor) to evaluate whether oral methylphenidate changes extracellular DA in the human brain in 11 healthy controls. We showed that oral methylphenidate (average dose 0.8 +/- 0.11 mg/kg) significantly increased extracellular DA in brain, as evidenced by a significant reduction in B(max)/K(d) (measure of D2 receptor availability) in striatum (20 +/- 12%; p < 0.0005). These results provide direct evidence that oral methylphenidate at doses within the therapeutic range significantly increases extracellular DA in human brain. This result coupled with recent findings of increased dopamine transporters in ADHD patients (which is expected to result in reductions in extracellular DA) provides a mechanistic framework for the therapeutic efficacy of methylphenidate. The increase in DA caused by the blockade of dopamine transporters by methylphenidate predominantly reflects an amplification of spontaneously released DA, which in turn is responsive to environmental stimulation. Because DA decreases background firing rates and increases signal-to-noise in target neurons, we postulate that the amplification of weak DA signals in subjects with ADHD by methylphenidate would enhance task-specific signaling, improving attention and decreasing distractibility. Alternatively methylphenidate-induced increases in DA, a neurotransmitter involved with motivation and reward, could enhance the salience of the task facilitating the "interest that it elicits" and thus improving performance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160455      PMCID: PMC6763805     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  192 in total

Review 1.  Experimental analyses of gene-brain-behavior relations: some notes on their application.

Authors:  C H Kennedy; M Caruso; T Thompson
Journal:  J Appl Behav Anal       Date:  2001

2.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

3.  Combined stimulant and antipsychotic treatment in adolescents with attention-deficit/hyperactivity disorder: a cross-sectional observational structural MRI study.

Authors:  L J S Schweren; C A Hartman; M P Zwiers; D J Heslenfeld; D van der Meer; B Franke; J Oosterlaan; J K Buitelaar; P J Hoekstra
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-11-14       Impact factor: 4.785

Review 4.  The addicted human brain: insights from imaging studies.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

5.  A Case Report of Methylphenidate-Induced Dyskinesia.

Authors:  Thomas W. Heinrich
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-08

6.  Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder.

Authors:  Nora D Volkow; Gene-Jack Wang; Dardo Tomasi; Scott H Kollins; Tim L Wigal; Jeffrey H Newcorn; Frank W Telang; Joanna S Fowler; Jean Logan; Christopher T Wong; James M Swanson
Journal:  J Neurosci       Date:  2012-01-18       Impact factor: 6.167

Review 7.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

8.  Acute and sub-chronic functional neurotoxicity of methylphenidate on neural networks in vitro.

Authors:  K V Gopal; B R Miller; G W Gross
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

Review 9.  Assessment and management of attention-deficit hyperactivity disorder in adults.

Authors:  Margaret Weiss; Candice Murray
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

10.  Regional cerebral blood flow in children with attention deficit hyperactivity disorder: comparison before and after methylphenidate treatment.

Authors:  Jae Sung Lee; Boong Nyun Kim; Eunjoo Kang; Dong Soo Lee; Yu Kyeong Kim; June-Key Chung; Myung Chul Lee; Soo Churl Cho
Journal:  Hum Brain Mapp       Date:  2005-03       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.